News | Radiation Therapy | May 10, 2019

Radiotherapy After Chemo May Improve Survival in Advanced Hodgkin's Lymphoma Patients

European study finds 7-10 percent increase in progression-free survival despite risks of toxic side effects

Radiotherapy After Chemo May Improve Survival in Advanced Hodgkin's Lymphoma Patients

May 10, 2019 — Patients with advanced Hodgkin's lymphoma who have large tumors at the time of diagnosis may benefit from radiotherapy after chemotherapy, even when all traces of the cancer appear to have gone. These findings are according to late-breaking results presented at the European Society for Radiotherapy and Oncology (ESTRO) 38 conference, April 26-30 in Milan, Italy.

Approximately 65-70 percent of patients with advanced stage Hodgkin's lymphoma can be cured by receiving six cycles of ABVD chemotherapy — which includes doxorubicin, bleomycin, vinblastine and dacarbazine — with or without subsequent radiotherapy. Currently, however, the addition of radiotherapy is controversial.

In a statement before the conference, Mario Levis, M.D., a co-author of the study, who is a radiation oncologist at the University of Turin, Italy, explained: "These patients can often have four or five decades of life expectancy ahead of them but, given this cure rate, the cancer treatment can result in a high risk of complications for many long-term survivors. For this reason, it's important that we give patients the most effective treatment for curing their cancer, while, at the same time, trying to keep the toxic side effects to a minimum."

To investigate whether radiotherapy after ABVD chemotherapy provided any benefit to these patients, researchers in several centers in Italy, led by Prof. Pier Luigi Zinzani, of the Institute of Haematology at the University of Bologna, and Prof. Umberto Ricardi, head of the Department of Oncology at the University of Turin and president of ESTRO, recruited 512 patients between 2008 and 2013 to a randomized clinical trial, HD0801.

Patients who had been treated successfully in the earlier, phase II part of the trial, and in whom positron emission tomography (PET) scans showed no trace of cancer both during and at the end of chemotherapy, were randomized to the phase III part of the trial to receive either radiotherapy in order to mop up any remaining cancer cells, or no further treatment.

In total, 354 patients had PET scans showing they were clear of cancer after the initial treatment. Of these, 116 (32.7 percent) had had large lesions (greater than 5cm in diameter) at the time of their diagnosis, and they were assigned to radiotherapy or no further treatment.

Levis and Ricardi found that more patients were alive three and five years later without their disease getting worse (known as progression-free survival) if they had been treated with radiotherapy than those who did not receive it.

Ricardi told the conference, "We found that three years later 92 percent of patients who received radiotherapy were still alive without disease progression compared to 82 percent of patients who did not receive it. After five years, these figures were 89 percent and 82 percent respectively. This suggests that patients with large tumors, who have responded to six cycles of ABVD chemotherapy, may still benefit from the addition of radiotherapy, with a survival benefit ranging from 7  to 10 percent at three and five years.

"This is something that should be considered carefully when deciding whether or not to give radiotherapy to these patients. The omission of radiotherapy would guarantee the prevention of radiation-induced toxic side effects, but, on the other hand, it exposes 10 percent of our, frequently young, patients to an increased risk of relapse and of even higher toxicity due to the heavy salvage therapies required when the disease returns," concluded Ricardi.

Nine patients who had been enrolled in the radiotherapy arm of the trial did not actually receive radiation treatment due to decisions made by their doctors, and the disease returned in five of them. This meant that when the data on the 116 patients were analyzed according to "intention to treat" (i.e. regardless of whether or not they had actually received the radiotherapy), there was little difference between the two groups in progression-free survival at three and five years. It was only when the researchers analyzed the data according to the treatments the patients had actually received (a "per protocol" analysis) that it was possible to see the benefit on survival for those treated with radiotherapy, although this was not statistically significant. This was mainly because of the small number of patients in whom the disease returned: five in the radiotherapy arm and 13 in the 'no further treatment' arm of the trial.

"The results of this trial do not provide definitive evidence on the role of radiotherapy after chemotherapy for patients with advanced Hodgkin's lymphoma and large tumors. However, the improvement in survival among those who did receive radiotherapy is not negligible. We think that the next step is for a meta-analysis of this and similar randomized trials in order to increase the robustness of the information we have on the best way to treat this disease," concluded Ricardi.

Prof. Yolande Lievens, past-president of ESTRO and head of the department of radiation oncology at Ghent University Hospital, Belgium, said, "As physicians our main aim is to treat our patients effectively while keeping any adverse side-effects from the treatment to the minimum. This is especially important for patients with a disease such as Hodgkin's lymphoma, many of whom can expect to be cured and live long after their treatment has finished. The results from this trial provide us with additional, important information to take into account when advising our patients on what might be the best treatment."

For more information: www.estro.org

Related Content

One in three adults treated for cancer may experience side effects from treatment they wish they had known more about, according to a new survey published today in the Journal of Oncology Practice
News | Clinical Trials | November 21, 2019
November 21, 2019 — One in three adults treated for cancer may experience side effects from treatment they wish they
 Prostate cancer MRI
News | Clinical Trials | November 15, 2019
November 15, 2019 — Theragnostics, which is developing innovative radiopharm
Members of Congress from both sides of the aisle issued a series of oversight letters to the Centers for Medicare and Medicaid Services (CMS) in recent months to urge the Agency to adjust its proposed radiation oncology advanced alternative payment model (RO Model)

Image by whitfieldink from Pixabay

News | Radiation Oncology | November 13, 2019
November 13, 2019 — Members of Congress from both sides of the aisle issued a series of oversight letters to the...
An image on Brigham and Women's Hospital's 7T MRI system

An image on Brigham and Women's Hospital's 7T MRI system. Image courtesy of Brigham and Women's Hospital

News | Magnetic Resonance Imaging (MRI) | November 13, 2019
November 13, 2019 — Increased immune system activity along the surface of the brain, or meningeal inflammation, may b
Image by Dr. Manuel González Reyes from Pixabay

Image by Dr. Manuel González Reyes from Pixabay 

News | SPECT Imaging | November 08, 2019
November 8, 2019 — Using ground-breaking technology, researchers at the...
This chest X-ray of a patient being treated for e-cigarette or vaping-associated lung injury shows lung opacities, densities and whitish cloud-like areas which are typically seen with unusual pneumonias, fluid in lungs or lung inflammation. Image courtesy of Intermountain Healthcare

This chest X-ray of a patient being treated for e-cigarette or vaping-associated lung injury shows lung opacities, densities and whitish cloud-like areas which are typically seen with unusual pneumonias, fluid in lungs or lung inflammation. Image courtesy of Intermountain Healthcare

News | Clinical Trials | November 08, 2019
November 8, 2019 — As the outbreak of lung injuries and deaths associated with e-cigarettes, or...
Unlike other technologies for imaging the placenta, pCASL MRI can distinguish maternal blood from fetal blood

Image courtesy of Pixabay

News | Clinical Trials | November 07, 2019
November 7, 2019 — A new imaging technique to track
Bladder Abdomen Pelvis image with DLCExpert
News | Artificial Intelligence | November 07, 2019
November 7, 2019 — Mirada Medical, a global leader in...
Liver cancer tumor scanning using an MRI
News | Proton Therapy | November 04, 2019
November 4, 2019 – Two new studies support and inform the use of proton radiation therapy to treat patients with hepa